» Articles » PMID: 18454568

Optimal Management of Nasal Congestion Caused by Allergic Rhinitis in Children: Safety and Efficacy of Medical Treatments

Overview
Journal Paediatr Drugs
Specialties Pediatrics
Pharmacology
Date 2008 May 6
PMID 18454568
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Nasal congestion is such a frequent and multifactorial occurrence in young children that parents and medical caregivers often overlook the need for medical intervention. However, children with congestion can suffer quality-of-life detriments resulting from sleep disturbance, learning impairment, and fatigue. Congestion also impairs the normal nasal breathing that is physiologically important for the efficient cleaning and conditioning of inspired air. Further, the most common cause of congestion, allergic rhinitis, is considered a potential risk factor for asthma. Published guidelines on the treatment of allergic rhinitis agree that management strategies in children should follow the same principles as in adults, while recognizing the need for dosage adjustments and being aware of unique safety issues. Intranasal corticosteroids, with robust effects in reducing congestion and good tolerability, remain a treatment of choice. Despite lingering concerns about the potential for growth suppression with these drugs, clinical evidence suggests a very low risk at prescribed dosages, especially with compounds that have a low systemic bioavailability. Oral antihistamines are commonly cited as first-line options for allergic rhinitis, although their effect on nasal congestion is relatively modest. First-generation antihistamines should not be administered to children because of their sedative properties, which can worsen learning problems associated with allergic rhinitis. Second-generation oral antihistamines are preferred, although this class is not completely devoid of adverse effects. Other treatments, such as a nasal antihistamine, decongestants, and immunotherapy, present varying levels of safety and tolerability issues in children.

Citing Articles

Allergic Rhinitis in Children: A Randomized Clinical Trial Targeted at Symptoms.

Mansi N, DAgostino G, Scire A, Morpurgo G, Gregori D, Gulati A Indian J Otolaryngol Head Neck Surg. 2015; 66(4):386-93.

PMID: 26396949 PMC: 4571470. DOI: 10.1007/s12070-014-0708-4.


Decongestants, antihistamines and nasal irrigation for acute sinusitis in children.

Shaikh N, Wald E Cochrane Database Syst Rev. 2014; (10):CD007909.

PMID: 25347280 PMC: 7182143. DOI: 10.1002/14651858.CD007909.pub4.

References
1.
Holm A, Fokkens W, Godthelp T, Mulder P, Vroom T, Rijntjes E . A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol Allied Sci. 1998; 23(1):69-73. DOI: 10.1046/j.1365-2273.1998.00096.x. View

2.
Ciprandi G, Tosca M, Milanese M, Schenone G, Ricca V . Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis: histamine and leukotriene antagonism. Eur Ann Allergy Clin Immunol. 2004; 36(2):67-70, 72. View

3.
Wolthers O, Pedersen S . Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy. 1994; 49(2):96-9. DOI: 10.1111/j.1398-9995.1994.tb00807.x. View

4.
Bender B . Cognitive effects of allergic rhinitis and its treatment. Immunol Allergy Clin North Am. 2005; 25(2):301-12, vi-vii. DOI: 10.1016/j.iac.2005.03.002. View

5.
Schenkel E, Skoner D, Bronsky E, Miller S, Pearlman D, Rooklin A . Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000; 105(2):E22. DOI: 10.1542/peds.105.2.e22. View